Literature DB >> 10839742

Growth in vascular cells and cytokine production by Chlamydia pneumoniae.

C A Gaydos1.   

Abstract

The proposed pathogenesis of Chlamydia pneumoniae in atherosclerosis is supported by the finding that C. pneumoniae can initiate and sustain growth in human vascular cells. In vitro growth of C. pneumoniae is found in macrophages, peripheral blood monocyte (PBMC)-derived macrophages, endothelial cells, and aortic artery smooth muscle cells. U-937 macrophages infected with C. pneumoniae are capable of transmitting the infection to human coronary artery endothelial cells (CAEC) with direct cellular contact. Production of cytokines by cells infected with C. pneumoniae indicates that the organism can stimulate the immune system. CAEC infected with C. pneumoniae produce more interleukin-8 than cells sham inoculated with negative control cells. When interferon-gamma is used to stimulate HEp-2 cells, U-937 cells, and PBMC (before infection with C. pneumoniae), inhibition of a productive growth cycle occurs in a dose-related response. Studies are needed to learn the relationship between productive infection and persistence, the ability of C. pneumoniae to affect the immune response, and the potential for C. pneumoniae to influence atheromatous lesions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10839742     DOI: 10.1086/315612

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested.

Authors:  J Thomas Grayston; Robert J Belland; Gerald I Byrne; Cho Chou Kuo; Julius Schachter; Walter E Stamm; Guangming Zhong
Journal:  Pathog Dis       Date:  2014-12-04       Impact factor: 3.166

2.  Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.

Authors:  Andrei Kutlin; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease.

Authors:  Tanyalak Parimon; Jason W Chien; Chris L Bryson; Mary B McDonell; Edmunds M Udris; David H Au
Journal:  Am J Respir Crit Care Med       Date:  2006-12-21       Impact factor: 21.405

4.  Newly characterized species-specific immunogenic Chlamydophila pneumoniae peptide reactive with murine monoclonal and human serum antibodies.

Authors:  Eric L Marston; Andrea V James; J Todd Parker; John C Hart; Teresa M Brown; Trudy O Messmer; Danny L Jue; Carolyn M Black; George M Carlone; Edwin W Ades; Jacquelyn Sampson
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

5.  Chlamydia pneumoniae antibodies and C-reactive protein levels in patients with abdominal aortic aneurysms.

Authors:  M A Sharif; D A McDowell; S A Badger
Journal:  ScientificWorldJournal       Date:  2013-12-28

Review 6.  Chlamydia pneumoniae and oxidative stress in cardiovascular disease: state of the art and prevention strategies.

Authors:  Marisa Di Pietro; Simone Filardo; Fiorenzo De Santis; Paola Mastromarino; Rosa Sessa
Journal:  Int J Mol Sci       Date:  2014-12-30       Impact factor: 5.923

Review 7.  Chlamydia pneumoniae-Mediated Inflammation in Atherosclerosis: A Meta-Analysis.

Authors:  Simone Filardo; Marisa Di Pietro; Alessio Farcomeni; Giovanna Schiavoni; Rosa Sessa
Journal:  Mediators Inflamm       Date:  2015-08-09       Impact factor: 4.711

Review 8.  Chlamydia pneumoniae infection in atherosclerotic lesion development through oxidative stress: a brief overview.

Authors:  Marisa Di Pietro; Simone Filardo; Fiorenzo De Santis; Rosa Sessa
Journal:  Int J Mol Sci       Date:  2013-07-19       Impact factor: 5.923

9.  Association between Chlamydia pneumoniae infection and lung cancer: a meta-analysis.

Authors:  Chunxi Wang; Naxin Zhang; Liang Gao
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.